Cargando…
Clinical outcomes of temocillin use for invasive Enterobacterales infections: a single-centre retrospective analysis
BACKGROUND: With increasing frequency of resistant Gram-negative bacteria, temocillin has potential utility in reducing carbapenem use. The 2020 EUCAST guideline changes temocillin breakpoints and reclassifies isolates with an MIC of 0.001–16 mg/L as ‘susceptible, increased exposure’ necessitating 6...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8210019/ https://www.ncbi.nlm.nih.gov/pubmed/34223083 http://dx.doi.org/10.1093/jacamr/dlab005 |
_version_ | 1783709230514044928 |
---|---|
author | Heard, Katie L Killington, Kieran Mughal, Nabeela Moore, Luke S P Hughes, Stephen |
author_facet | Heard, Katie L Killington, Kieran Mughal, Nabeela Moore, Luke S P Hughes, Stephen |
author_sort | Heard, Katie L |
collection | PubMed |
description | BACKGROUND: With increasing frequency of resistant Gram-negative bacteria, temocillin has potential utility in reducing carbapenem use. The 2020 EUCAST guideline changes temocillin breakpoints and reclassifies isolates with an MIC of 0.001–16 mg/L as ‘susceptible, increased exposure’ necessitating 6 g/day rather than the previous 4 g/day, associated with significant cost implications. OBJECTIVES: We explore the clinical utility and treatment failure rate of temocillin at 4 g/day dosing. METHODS: All adult inpatient electronic prescriptions of temocillin (3 days or greater) from March 2016 to October 2019 were retrieved using a clinical decision support system (ICNET(®)). Treatment success was defined as survival, no switch to broad-spectrum agent for the same indication and no subsequent recrudescence of infection, occurring within 30 days. RESULTS: Temocillin was used in 205 eligible patient-episodes, median age 79 years (IQR : 71–87 years), 42.4% female. Median temocillin course length was 5.9 days (IQR : 4.6–7.8 days). Indications for use: urinary tract infection (UTI) (n = 141), pneumonia (n = 53), other (n = 11). In total, 144 (70.2%) patients had targeted treatment; 74 (36.1%) against Escherichia coli, 70 (34.4%) other Enterobacterales. A total of 130 (63%) patients received 4 g/day; the remaining patients had reduced renal function with dosing in accordance with guidance. Overall temocillin treatment success was 79.5%; highest when used to treat UTI 85.8% (versus 67.9% in respiratory infections, P = 0.008). Empirical treatment demonstrated 82.0% (50/61) success [versus 78.5% (113/144) among targeted treatment, P = 0. 71]. CONCLUSIONS: Temocillin at 4 g/day is an effective and safe alternative in treating patients with Gram-negative infections, but should be considered in the context of patient age and comorbidities. Increased dosing or alternate strategies may be indicated when the infection is not of a urinary source. |
format | Online Article Text |
id | pubmed-8210019 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-82100192021-07-02 Clinical outcomes of temocillin use for invasive Enterobacterales infections: a single-centre retrospective analysis Heard, Katie L Killington, Kieran Mughal, Nabeela Moore, Luke S P Hughes, Stephen JAC Antimicrob Resist Original Article BACKGROUND: With increasing frequency of resistant Gram-negative bacteria, temocillin has potential utility in reducing carbapenem use. The 2020 EUCAST guideline changes temocillin breakpoints and reclassifies isolates with an MIC of 0.001–16 mg/L as ‘susceptible, increased exposure’ necessitating 6 g/day rather than the previous 4 g/day, associated with significant cost implications. OBJECTIVES: We explore the clinical utility and treatment failure rate of temocillin at 4 g/day dosing. METHODS: All adult inpatient electronic prescriptions of temocillin (3 days or greater) from March 2016 to October 2019 were retrieved using a clinical decision support system (ICNET(®)). Treatment success was defined as survival, no switch to broad-spectrum agent for the same indication and no subsequent recrudescence of infection, occurring within 30 days. RESULTS: Temocillin was used in 205 eligible patient-episodes, median age 79 years (IQR : 71–87 years), 42.4% female. Median temocillin course length was 5.9 days (IQR : 4.6–7.8 days). Indications for use: urinary tract infection (UTI) (n = 141), pneumonia (n = 53), other (n = 11). In total, 144 (70.2%) patients had targeted treatment; 74 (36.1%) against Escherichia coli, 70 (34.4%) other Enterobacterales. A total of 130 (63%) patients received 4 g/day; the remaining patients had reduced renal function with dosing in accordance with guidance. Overall temocillin treatment success was 79.5%; highest when used to treat UTI 85.8% (versus 67.9% in respiratory infections, P = 0.008). Empirical treatment demonstrated 82.0% (50/61) success [versus 78.5% (113/144) among targeted treatment, P = 0. 71]. CONCLUSIONS: Temocillin at 4 g/day is an effective and safe alternative in treating patients with Gram-negative infections, but should be considered in the context of patient age and comorbidities. Increased dosing or alternate strategies may be indicated when the infection is not of a urinary source. Oxford University Press 2021-02-14 /pmc/articles/PMC8210019/ /pubmed/34223083 http://dx.doi.org/10.1093/jacamr/dlab005 Text en © The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Heard, Katie L Killington, Kieran Mughal, Nabeela Moore, Luke S P Hughes, Stephen Clinical outcomes of temocillin use for invasive Enterobacterales infections: a single-centre retrospective analysis |
title | Clinical outcomes of temocillin use for invasive Enterobacterales infections: a single-centre retrospective analysis |
title_full | Clinical outcomes of temocillin use for invasive Enterobacterales infections: a single-centre retrospective analysis |
title_fullStr | Clinical outcomes of temocillin use for invasive Enterobacterales infections: a single-centre retrospective analysis |
title_full_unstemmed | Clinical outcomes of temocillin use for invasive Enterobacterales infections: a single-centre retrospective analysis |
title_short | Clinical outcomes of temocillin use for invasive Enterobacterales infections: a single-centre retrospective analysis |
title_sort | clinical outcomes of temocillin use for invasive enterobacterales infections: a single-centre retrospective analysis |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8210019/ https://www.ncbi.nlm.nih.gov/pubmed/34223083 http://dx.doi.org/10.1093/jacamr/dlab005 |
work_keys_str_mv | AT heardkatiel clinicaloutcomesoftemocillinuseforinvasiveenterobacteralesinfectionsasinglecentreretrospectiveanalysis AT killingtonkieran clinicaloutcomesoftemocillinuseforinvasiveenterobacteralesinfectionsasinglecentreretrospectiveanalysis AT mughalnabeela clinicaloutcomesoftemocillinuseforinvasiveenterobacteralesinfectionsasinglecentreretrospectiveanalysis AT moorelukesp clinicaloutcomesoftemocillinuseforinvasiveenterobacteralesinfectionsasinglecentreretrospectiveanalysis AT hughesstephen clinicaloutcomesoftemocillinuseforinvasiveenterobacteralesinfectionsasinglecentreretrospectiveanalysis |